Targovax is invited to present at upcoming investor and industry conferences
Oslo, Norway, 28 November 2018 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences:
Date: 29 November 2018
Venue: Nordic-American Life Science Conference, NYC, US
Keynote panel: The Allure and Challenges of Nordic Healthcare Acquisitions and Partnerships
Time: 12:30 PM EST
Time: 3:00 PM EST
Presenter: Torbjørn Furuseth, CFO
Date: 5 December 2018
Venue: 4th Annual Oncolytic Virotherapy Summit, Boston, USA
Time: 12:30 PM EST
Presenter: Erik Digman Wiklund, CBO
Panel Discussion: Comparing and Contrasting Virus Types
Time: 4:30 PM EST
The 4th Oncolytic Virotherapy Summit is the leading international conference in the oncolytic virotherapy field for biotech and pharma drug developers to gain scientific and clinical trial updates. In the above mentioned panel discussion, Erik Digman Wiklund, CBO of Targovax, will, together with William Jia, CSO of Virogin, Robert Coffin, CEO of Replimune and Stephen Russell, CEO of Vyriad discuss wild-type and newer generations viruses expressing immune stimulatory payloads or tumor antigens.
The presentations will be available to download at www.targovax.com following these events.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Simon Conway/Stephanie Cuthbert – FTI Consulting (International)
Phone: +44 20 3727 1000
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It has been shown to activate the immune system to generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced both local and systemic innate and adaptive immune activation, which has been associated with clinical benefit. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase II trial, with a phase Ib safety lead-in cohort. Another trial, in advanced melanoma, is expected to produce important proof of concept data for checkpoint inhibitor refractory patients.
Targovax is also developing a neo-antigen cancer vaccine targeting tumors that express mutated forms of RAS – mutations known to drive cancer. The TG vaccine program has shown a signal of efficacy compared to historical control in a 32-patient trial with TG01 in resected pancreatic cancer. A next generation product candidate, TG02 is currently tested as monotherapy and will also be tested in combination with KEYTRUDA® (an anti-PD1 check point inhibitor, CPI).